The Role of Peroxisome Proliferator-Activated Receptor β/δ on the Inflammatory Basis of Metabolic Disease
Teresa Coll,
Emma Barroso,
David Álvarez-Guardia,
Lucía Serrano,
Laia Salvadó,
Manuel Merlos,
Xavier Palomer,
Manuel Vázquez-Carrera
Affiliations
Teresa Coll
Department of Pharmacology and Therapeutic Chemistry, CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM)-Instituto de Salud Carlos III and Institut de Biomedicina de la Universitat de Barcelona (IBUB), Faculty of Pharmacy, University of Barcelona, Diagonal 643, 08028 Barcelona, Spain
Emma Barroso
Department of Pharmacology and Therapeutic Chemistry, CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM)-Instituto de Salud Carlos III and Institut de Biomedicina de la Universitat de Barcelona (IBUB), Faculty of Pharmacy, University of Barcelona, Diagonal 643, 08028 Barcelona, Spain
David Álvarez-Guardia
Department of Pharmacology and Therapeutic Chemistry, CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM)-Instituto de Salud Carlos III and Institut de Biomedicina de la Universitat de Barcelona (IBUB), Faculty of Pharmacy, University of Barcelona, Diagonal 643, 08028 Barcelona, Spain
Lucía Serrano
Department of Pharmacology and Therapeutic Chemistry, CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM)-Instituto de Salud Carlos III and Institut de Biomedicina de la Universitat de Barcelona (IBUB), Faculty of Pharmacy, University of Barcelona, Diagonal 643, 08028 Barcelona, Spain
Laia Salvadó
Department of Pharmacology and Therapeutic Chemistry, CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM)-Instituto de Salud Carlos III and Institut de Biomedicina de la Universitat de Barcelona (IBUB), Faculty of Pharmacy, University of Barcelona, Diagonal 643, 08028 Barcelona, Spain
Manuel Merlos
Department of Pharmacology and Therapeutic Chemistry, CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM)-Instituto de Salud Carlos III and Institut de Biomedicina de la Universitat de Barcelona (IBUB), Faculty of Pharmacy, University of Barcelona, Diagonal 643, 08028 Barcelona, Spain
Xavier Palomer
Department of Pharmacology and Therapeutic Chemistry, CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM)-Instituto de Salud Carlos III and Institut de Biomedicina de la Universitat de Barcelona (IBUB), Faculty of Pharmacy, University of Barcelona, Diagonal 643, 08028 Barcelona, Spain
Manuel Vázquez-Carrera
Department of Pharmacology and Therapeutic Chemistry, CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM)-Instituto de Salud Carlos III and Institut de Biomedicina de la Universitat de Barcelona (IBUB), Faculty of Pharmacy, University of Barcelona, Diagonal 643, 08028 Barcelona, Spain
The pathophysiology underlying several metabolic diseases, such as obesity, type 2 diabetes mellitus, and atherosclerosis, involves a state of chronic low-level inflammation. Evidence is now emerging that the nuclear receptor Peroxisome Proliferator-Activated Receptor (PPAR)β/δ ameliorates these pathologies partly through its anti-inflammatory effects. PPARβ/δ activation prevents the production of inflammatory cytokines by adipocytes, and it is involved in the acquisition of the anti-inflammatory phenotype of macrophages infiltrated in adipose tissue. Furthermore, PPARβ/δ ligands prevent fatty acid-induced inflammation in skeletal muscle cells, avoid the development of cardiac hypertrophy, and suppress macrophage-derived inflammation in atherosclerosis. These data are promising and suggest that PPARβ/δ ligands may become a therapeutic option for preventing the inflammatory basis of metabolic diseases.
